Reply to: "Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?"

Affiliations

¹ IFI-Institute for Interdisciplinary Medicine, Hamburg, Germany. Electronic address: buggisch@ifi-medizin.de.
² University Hospital Frankfurt, Frankfurt am Main, Germany.

Comment

Peter Buggisch et al. J Hepatol. 2018 Aug.

. 2018 Aug;69(2):553.

doi: 10.1016/j.jhep.2018.05.005. Epub 2018 Jun 7.

¹ IFI-Institute for Interdisciplinary Medicine, Hamburg, Germany. Electronic address: buggisch@ifi-medizin.de.
² University Hospital Frankfurt, Frankfurt am Main, Germany.

No abstract available

Comment on

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, Boeker K, Zimmermann T, Teuber G, Vornkahl HP, Simon KG, Niederau C, Wedemeyer H, Zeuzem S. Buggisch P, et al. J Hepatol. 2018 Apr;68(4):663-671. doi: 10.1016/j.jhep.2017.11.009. Epub 2017 Nov 11. J Hepatol. 2018. PMID: 29133244
Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?
Ojha RP, Steyerberg EW. Ojha RP, et al. J Hepatol. 2018 Aug;69(2):551-553. doi: 10.1016/j.jhep.2018.02.037. Epub 2018 May 26. J Hepatol. 2018. PMID: 29843905 No abstract available.